Effect of Statins on the Development of Renal Dysfunction

American Journal of Cardiology

Volumn 101, Issue 7, 2008, Pages 975-979

  Sukhija, Rishi ^a   Bursac, Zoran ^a   Kakar, Priyanka ^a   Fink, Louis ^a   Fort, Charlton ^a   Satwani, Shiyam ^a   Aronow, Wilbert S ^b   Bansal, Darpan ^a   Mehta, Jawahar L ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING;

AGED; CREATININE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 40949133832     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.11.042     Document Type: Article

References (22)

1. Fried L.F., Orchard T.J., and Kasiske B.L. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 59 (2001) 260-269
2. Tonelli M., Isles C., and Craven T. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary artery disease. Circulation 112 (2005) 171-178
3. Tonelli M., Moye L., Sacks F.M., Cole T., and Curhan G.C. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 14 (2003) 1605-1613
4. Muntner P., Coresh J., Smith J.C., Eckfeldt J., and Klag M.J. Plasma lipids and risk of developing renal dysfunction: the Atherosclerosis Risk In Communities Study. Kidney Int 58 (2000) 293-301
5. Manttari M., Tiula E., Alikoski T., and Manninen V. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension 26 (1995) 670-675
6. Schaeffner E.S., Kurth T., Curhan G.C., Glynn R.J., Rexrode K.M., Baigent C., Buring J.E., and Gaziano J.M. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 14 (2003) 2084-2091
7. Sandhu S., Wiebe N., Fried L.F., and Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 17 (2006) 2006-2016
8. Ozsoy R.C., van der Steeg W.A., Kastelein J.J., Arisz L., and Koopman M.G. Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastatin. Nephrol Dial Transplant 22 (2007) 1578-1586
9. Tonelli M., Moye L., Sacks F.M., Kiberd B., Curhan G., and Cholesterol and Recurrent Events (CARE) Trial Investigators. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 138 (2003) 98-104
10. Tonelli M., Sacks F., Pfeffer M., Jhangri G.S., Curhan G., and Cholesterol and Recurrent Events (CARE) Trial Investigators. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 68 (2005) 237-245
11. Avram M.M. Similarities between glomerular sclerosis and atherosclerosis in human renal biopsy specimens: a role for lipoprotein glomerulopathy. Am J Med 87 (1989) 39N-41N
12. Rovin B.H., and Tan L.C. LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney Int 43 (1993) 218-225
13. Magil A.B., Wadsworth L.D., and Loewen M. Monocytes and human renal glomerular disease: a quantitative evaluation. Lab Invest 44 (1981) 27-33
14. Lee H.S., and Kim Y.S. Identification of oxidized low density lipoprotein in human renal biopsies. Kidney Int 54 (1998) 848-856
15. Yoshimura A., Nemoto T., Sugenoya Y., Inui K., Watanabe S., Inoue Y., Sharif S., Yokota N., Uda S., Morita H., and Ideura T. Effect of simvastatin on proliferative nephritis and cell-cycle protein expression. Kidney Int 56 suppl 71 (1999) S84-S87
16. Li C., Yang C.W., Park J.H., Lim S.W., Sun B.K., Jung J.Y., Kim S.B., Kim Y.S., Kim J., and Bang B.K. Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy. Am J Renal Physiol 286 (2004) F46-F57
17. Yamashita T., Kawashima S., Miwa Y., Ozaki M., Namiki M., Hirase T., Inoue N., Hirata K., and Yokoyama M. A 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor reduces hypertensive nephrosclerosis in stroke-prone spontaneously hypertensive rats. J Hypertens 20 (2002) 2465-2473
18. Li D.Y., Chen H.J., and Mehta J.L. Statins inhibit oxidized-LDL-mediated LOX-1 expression, uptake of oxidized-LDL and reduction in PKB phosphorylation. Cardiovasc Res 52 (2001) 130-135
19. Li D., Chen H., Romeo F., Sawamura T., Saldeen T., and Mehta J.L. Statins modulate oxidized low-density lipoprotein-mediated adhesion molecule expression in human coronary artery endothelial cells: role of LOX-1. J Pharmacol Exp Ther 302 (2002) 601-605
20. Taverner D., Mackay I.G., Craig K., and Watson M.L. The effects of selective beta-adrenoceptor antagonists and partial agonist activity on renal function during exercise in normal subjects and those with moderate renal impairment. Br J Clin Pharmacol 32 (1991) 387-391
21. Ljungman S., Wikstrand J., Hartford M., Aurell M., Lindstedt G., and Berglund G. Effects of long-term antihypertensive treatment and aging on renal function and albumin excretion in primary hypertension. Am J Hypertens 6 (1993) 554-563
22. Schmieder R.E. Nephroprotectioin by antihypertensive agents. J Cardiovasc Pharmacol 24 suppl 2 (1994) S55-S64